1.38
-0.14(-9.21%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.41 |
| Day High | 1.47 |
| Day Low | 1.3 |
| 52-Week High | 4.74 |
| 52-Week Low | 0.36 |
| Volume | 4.72M |
| Average Volume | 13.7M |
| Market Cap | 165.07M |
| PE | -0.71 |
| EPS | -1.95 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 1.13 |
| Change | -0.14 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $66.09 as of February 14, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $215.96 as of February 14, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
GlobeNewswire Inc.
Feb 10, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The pr
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
GlobeNewswire Inc.
Feb 05, 2025 2:30 PM GMT
Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,000 deaths and 665,000 hospitalizations in 2024, as well as a lifetime o
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are su